NanoViricides Anti-HIV Lead Drug Candidate Demonstrated Substantial Improvement in Survival Time in Animal Model
Monday June 16, 7:00 am ET
Results Better Than Combination Therapy in Double-Blind Animal Study
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB:
NNVC.OB), (the
“Company
”) said that its lead anti-HIV drug candidate demonstrated markedly superior survival results in the test animals when compared to those animals given the anti-HIV
“combo cocktail
” in a double-blind animal study. The three-drug combo
“cocktail
” used for comparison is one of the most frequently used triple combination therapies in humans.
Full text here.
A
No comments:
Post a Comment